跳至主要内容
临床试验/NCT01003028
NCT01003028尚未招募4 期

Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2024年11月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
尚未招募
入组人数
160
试验地点
1
主要终点
hypotension more than 25% from baseline

研究概览

简要总结

This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18-70 year old
  • ASA class 1-3 scheduled for elective surgery

排除标准

  • history of neurologic or mental disorder
  • uncontrolled pulmonary or cardiovascular disease
  • history of adverse reactions to opioids
  • history of drug abuse

研究组 & 干预措施

Limited

Experimental

Limit the maximum plasma concentration target to 9.8 ng/ml

干预措施: Remifentanil (Limited) - Target Controlled Infusion system (Drug)

Control

Active Comparator

Use 20 ng/ml as max plasma concentration

干预措施: Remifentanil (Control) - Target Controlled Infusion system (Drug)

结局指标

主要结局

hypotension more than 25% from baseline

时间窗: during remifentanil loading

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chul-Woo Jung

Assistant professor

Seoul National University Hospital

研究点 (1)

Loading locations...

相似试验